Tumor Biology

, Volume 35, Issue 12, pp 12189–12200 | Cite as

MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data

  • Xiang Tan
  • Mingwu Chen
Research Article


Gene expression microarrays are widely used to investigate molecular targets in cancers, including lung cancer. In this study, we analyzed online non-small cell lung cancer (NSCLC) microarray databases, to screen the key genes and pathways related to NSCLC by bioinformatics analyses. And then, the expression levels of two selected genes in the down-regulated co-pathways, myosin light chain kinase (MYLK) and myosin regulatory light chain 9 (MYL9), were determined in tumor, paired paraneoplastic, and normal lung tissues. First, gene set enrichment analysis and meta-analysis were conducted to identify key genes and pathways that contribute to NSCLC carcinogenesis. Second, using the total RNA and protein extracted from lung cancer tissues (n = 240), adjacent non-cancer tissues (n = 240), and normal lung tissues (n = 300), we examined the MYLK and MYL9 expression levels by quantitative real-time PCR and Western blot. Finally, we explored the correlations between mRNA and protein expressions of these two genes and the clinicopathological parameters of NSCLC. Fifteen up-regulated and nine down-regulated co-pathways were observed. A number of differentially expressed genes (CALM1, THBS1, CSF3, BMP2, IL6ST, MYLK, ROCK2, IL3RA, MYL9, PPP2CA, CSF2RB, CNAQ, GRIA2, IL10RA, IL10RB, IL11RA, LIFR, PLCB4, and RAC3) were identified (P < 0.01) in the down-regulated co-pathways. The expression levels of MYLK and MYL9, which act downstream of the vascular smooth muscle contraction signal pathway and focal adhesion pathway, were significantly lower in cancer tissue than those in the paraneoplastic and normal tissues (P < 0.05). Moreover, the expression levels of these two genes in stages III and IV NSCLC were significantly increased, when compared to stages I and II, and expressions levels in NSCLC with lymphatic metastasis were higher than that without lymphatic metastasis (P < 0.05). Additionally, significant lower expression levels of the two genes were found in smokers than in nonsmokers (P < 0.05). In contrast, gender, differentiated degrees, and pathohistological type appeared to have no impact on these gene expressions (P > 0.05). These findings suggested that low MYLK and MYL9 expressions might be associated with the development of NSCLC. These genes may be also relevant to NSCLC metastasis. Future investigations with large sample sizes needed to verify these findings.


MYLK MYL9 Expression QRT-PCR WB GSEA Meta-analysis 



This work was supported by the Guangxi scientific research and technology development project (No. 10124001A-47).

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Gene Chromosome Cancer. 2013;52:356–69.CrossRefGoogle Scholar
  3. 3.
    van Zandwijk N. New methods for early diagnosis of lung cancer. Lung Cancer. 2002;38:S9–11. Amsterdam, Netherlands.PubMedCrossRefGoogle Scholar
  4. 4.
    Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, et al. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. J Thorac Oncol. 2013;8:1148–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet. 2005;37(Suppl):S31–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. Ncbi geo: mining tens of millions of expression profiles—database and tools update. Nucleic Acids Res. 2007;35:D760–5.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. Notch1 directly regulates c-myc and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103:18261–6.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Greenbaum D, Jansen R, Gerstein M. Analysis of mRNA expression and protein abundance data: an approach for the comparison of the enrichment of features in the cellular population of proteins and transcripts. Bioinformatics. 2002;18:585–96. Oxford, England.PubMedCrossRefGoogle Scholar
  10. 10.
    Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–64. Oxford, England.PubMedCrossRefGoogle Scholar
  12. 12.
    Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy—analysis of Affymetrix Genechip data at the probe level. Bioinformatics. 2004;20:307–15. Oxford, England.PubMedCrossRefGoogle Scholar
  13. 13.
    Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3, Article3.PubMedGoogle Scholar
  15. 15.
    Daves MH, Hilsenbeck SG, Lau CC, Man TK. Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genet. 2011;4:56.Google Scholar
  16. 16.
    Chen ZJ, Le HB, Zhang YK, Qian LY, Li WD. Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features. J Int Med Res. 2009;37:551–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Oshika Y, Masuda K, Tokunaga T, Hatanaka H, Kamiya T, Abe Y, et al. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res. 1998;4:1785–8.PubMedGoogle Scholar
  18. 18.
    Chen ZL, Zhao SH, Wang Z, Qiu B, Li BZ, Zhou F, et al. Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer. Chin J Cancer. 2011;30:62–8.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Ivanova M, Abner S, Pierce Jr W, Klinge C. Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses. Proteome Sci. 2011;9:60.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Choi YJ, Kim ST, Park KH, Oh SC, Seo JH, Shin SW, et al. The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. Med Oncol. 2012;29:582–8. Northwood, London, England.PubMedCrossRefGoogle Scholar
  21. 21.
    Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009;66:319–26. Amsterdam, Netherlands.PubMedCrossRefGoogle Scholar
  22. 22.
    Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005;80:1028–32.PubMedCrossRefGoogle Scholar
  23. 23.
    McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004;91:1993–5.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Haura EB, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer. 2006;7:273–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Ganapathi MK, Weizer AK, Borsellino S, Bukowski RM, Ganapathi R, Rice T, et al. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components. Cell Growth Differ. 1996;7:923–9.PubMedGoogle Scholar
  26. 26.
    Oshika Y, Nakamura M, Hatanaka H, Abe Y, Tokunaga T, Ohnishi Y, et al. A human lung cancer xenograft producing granulocyte-colony stimulating factor and parathyroid hormone-related protein. Oncol Rep. 1998;5:359–62.PubMedGoogle Scholar
  27. 27.
    Liu P, Morrison C, Wang L, Xiong D, Vedell P, Cui P, et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis. 2012;33:1270–6.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Minamiya Y, Nakagawa T, Saito H, Matsuzaki I, Taguchi K, Ito M, et al. Increased expression of myosin light chain kinase mRNA is related to metastasis in non-small cell lung cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2005;26:153–7.CrossRefGoogle Scholar
  29. 29.
    MacDonald JW, Ghosh D. COPA—cancer outlier profile analysis. Bioinformatics. 2006;22:2950–1. Oxford, England.PubMedCrossRefGoogle Scholar
  30. 30.
    Fang X, Netzer M, Baumgartner C, Bai C, Wang X. Genetic network and gene set enrichment analysis to identify biomarkers related to cigarette smoking and lung cancer. Cancer Treat Rev. 2013;39:77–88.PubMedCrossRefGoogle Scholar
  31. 31.
    Lazar V, Garcia JG. A single human myosin light chain kinase gene (MLCK; MYLK). Genomics. 1999;57:256–67.PubMedCrossRefGoogle Scholar
  32. 32.
    Somlyo AP, Somlyo AV. Signal transduction by g-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin ii. J Physiol. 2000;522(Pt 2):177–85.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin ii: modulated by g proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325–58.PubMedGoogle Scholar
  34. 34.
    Bresnick AR. Molecular mechanisms of nonmuscle myosin-ii regulation. Curr Opin Cell Biol. 1999;11:26–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem. 2001;276:4527–30.PubMedCrossRefGoogle Scholar
  36. 36.
    Shehadeh LA, Webster KA, Hare JM, Vazquez-Padron RI. Dynamic regulation of vascular myosin light chain (MYL9) with injury and aging. PLoS ONE. 2011;6:e25855.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Hu W, Feng P. Myosin light chain kinase is involved in the mechanism of gastrointestinal dysfunction in diabetic rats. Dig Dis Sci. 2012;57:1197–202.PubMedCrossRefGoogle Scholar
  38. 38.
    Han YJ, Ma SF, Yourek G, Park YD, Garcia JG. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J. 2011;25:2305–12.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee WS, Seo G, Shin HJ, Yun SH, Yun H, Choi N, et al. Identification of differentially expressed genes in microsatellite stable hnpcc and sporadic colon cancer. J Surg Res. 2008;144:29–35.PubMedCrossRefGoogle Scholar
  40. 40.
    Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y, et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers. 2012;32:195–202.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Coniglio SJ, Zavarella S, Symons MH. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol Cell Biol. 2008;28:4162–72.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Fincham VJ, James M, Frame MC, Winder SJ. Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBO J. 2000;19:2911–23.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Ren K, Jin H, Bian C, He H, Liu X, Zhang S, et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem. 2008;283:35598–605.PubMedCrossRefGoogle Scholar
  44. 44.
    Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004;14:241–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Berridge MJ. Smooth muscle cell calcium activation mechanisms. J Physiol. 2008;586:5047–61.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Zhou X, Liu Y, You J, Zhang H, Zhang X, Ye L. Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Lett. 2008;270:312–27.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Cardiothoracic Surgery, First Affiliated HospitalGuangxi Medical UniversityNanningChina

Personalised recommendations